The FDA on August 26, 2022, approved PEMAZYRE® (Pemigatinib) for adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with Fibroblast Growth Factor Receptor 1 (FGFR1) rearrangement. PEMAZYRE® is a product of Incyte Corporation.
Other Pages – Bottom Ad
Advertisement
Subscribe
